Top-Rated StocksTop-RatedNASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Forecast, Price & News $29.18 +1.03 (+3.66%) (As of 06/8/2023 ET) Add Compare Share Share Today's Range$27.35▼$29.1850-Day Range$19.01▼$29.1852-Week Range$4.48▼$30.30Volume385,419 shsAverage Volume290,043 shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$25.29 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media MoonLake Immunotherapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside13.3% Downside$25.29 Price TargetShort InterestBearish13.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$11.60 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.00) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.02 out of 5 starsMedical Sector927th out of 981 stocksPharmaceutical Preparations Industry453rd out of 475 stocks 1.5 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.29, MoonLake Immunotherapeutics has a forecasted downside of 13.3% from its current price of $29.18.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.55% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently increased by 30.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 0.6 News and Social Media Coverage Search InterestOnly 6 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat Follows4 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,601,089.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.13% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.00) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -25.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -25.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 22.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MoonLake Immunotherapeutics (NASDAQ:MLTX) StockMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.Read More Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MLTX Stock News HeadlinesMay 30, 2023 | benzinga.comThinking about buying stock in Comfort Systems, MoonLake Immunotherapeutics, Limbach, KBR, or Arcosa?May 27, 2023 | finance.yahoo.comMLTX - MoonLake ImmunotherapeuticsJune 8, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 26, 2023 | finance.yahoo.comMoonLake Immunotherapeutics (MLTX) Is a Great Choice for 'Trend' Investors, Here's WhyMay 26, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.29 Average PT from BrokeragesMay 18, 2023 | americanbankingnews.comCritical Survey: MoonLake Immunotherapeutics (MLTX) and Its CompetitorsMay 18, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for MoonLake Immunotherapeutics' Q2 2023 Earnings (NASDAQ:MLTX)May 17, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 3%June 8, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Software" to Revolutionize WarfareThis breakthrough will change "the way wars will be fought, and won, for years to come." - Chairman of the Joint Chief of Staff, General Mark Milley Get the name of the company supplying it to the U.S. Army here >>>May 17, 2023 | americanbankingnews.comMoonLake Immunotherapeutics Forecasted to Post FY2023 Earnings of ($0.92) Per Share (NASDAQ:MLTX)May 17, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for MoonLake Immunotherapeutics (NASDAQ:MLTX) Issued By SVB LeerinkMay 17, 2023 | americanbankingnews.comQ2 2023 EPS Estimates for MoonLake Immunotherapeutics (NASDAQ:MLTX) Boosted by HC WainwrightMay 15, 2023 | markets.businessinsider.comBTIG Sticks to Its Buy Rating for MoonLake Immunotherapeutics (MLTX)May 13, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Reaches New 12-Month High at $29.59May 12, 2023 | finanznachrichten.deMoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 12, 2023 | finance.yahoo.comMoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business UpdateMay 11, 2023 | finance.yahoo.comWhy MoonLake (MLTX) Might Surprise This Earnings SeasonMay 10, 2023 | finance.yahoo.comHere's Why Momentum in MoonLake Immunotherapeutics (MLTX) Should Keep goingMay 10, 2023 | markets.businessinsider.comMoonLake Immunotherapeutics (MLTX) Gets a Buy from H.C. WainwrightMay 8, 2023 | americanbankingnews.comMoonLake Immunotherapeutics' (MLTX) Reiterates Rating Reiterated at 22nd Century GroupMay 7, 2023 | americanbankingnews.comMoonLake Immunotherapeutics to Post Q1 2024 Earnings of ($0.44) Per Share, HC Wainwright Forecasts (NASDAQ:MLTX)May 5, 2023 | msn.comHC Wainwright & Co. Reiterates MoonLake Immunotherapeutics - (MLTX) Buy RecommendationMay 4, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)May 3, 2023 | finance.yahoo.comMoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supplyMay 3, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Shares Gap Up to $21.30May 3, 2023 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Receives $25.29 Average Target Price from AnalystsMay 2, 2023 | msn.comGuggenheim Initiates Coverage of MoonLake Immunotherapeutics - (MLTX) with Buy RecommendationSee More Headlines MLTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Company Calendar Last Earnings3/20/2023Today6/08/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Forecast$25.29 High Stock Price Forecast$36.00 Low Stock Price Forecast$16.00 Forecasted Upside/Downside-13.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-49,970,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.52% Return on Assets-52.13% Debt Debt-to-Equity RatioN/A Current Ratio9.14 Quick Ratio9.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.30 per share Price / Book22.45Miscellaneous Outstanding Shares52,700,000Free Float44,654,000Market Cap$1.54 billion OptionableNot Optionable Beta0.93 Key ExecutivesDr. Jorge Santos da Silva (Age 45)Co-Founder, CEO & Director Comp: $460.29kDr. Kristian Reich (Age 57)Co-Founder & Chief Scientific Officer Comp: $489.9kMr. Matthias Bodenstedt (Age 35)Chief Financial Officer Comp: $324.91kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGen. CounselAnnett ZippelDirector of People & CultureMs. Nuala BrennanChief Clinical Devel. OfficerMore ExecutivesKey CompetitorsArcus BiosciencesNYSE:RCUSTaro Pharmaceutical IndustriesNYSE:TARO89bioNASDAQ:ETNBDynavax TechnologiesNASDAQ:DVAXAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 258,378 shares on 5/18/2023Ownership: 0.575%Balyasny Asset Management L.P.Sold 20,292 shares on 5/16/2023Ownership: 0.375%Ally Bridge Group NY LLCBought 72,850 shares on 5/16/2023Ownership: 0.138%Jane Street Group LLCBought 26,034 shares on 5/16/2023Ownership: 0.049%Geode Capital Management LLCBought 5,658 shares on 5/16/2023Ownership: 0.032%View All Insider TransactionsView All Institutional Transactions MLTX Stock - Frequently Asked Questions Should I buy or sell MoonLake Immunotherapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MLTX shares. View MLTX analyst ratings or view top-rated stocks. What is MoonLake Immunotherapeutics' stock price forecast for 2023? 11 Wall Street analysts have issued twelve-month price objectives for MoonLake Immunotherapeutics' stock. Their MLTX share price forecasts range from $16.00 to $36.00. On average, they predict the company's share price to reach $25.29 in the next twelve months. This suggests that the stock has a possible downside of 13.3%. View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts. How have MLTX shares performed in 2023? MoonLake Immunotherapeutics' stock was trading at $10.50 on January 1st, 2023. Since then, MLTX stock has increased by 177.9% and is now trading at $29.18. View the best growth stocks for 2023 here. Are investors shorting MoonLake Immunotherapeutics? MoonLake Immunotherapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,320,000 shares, an increase of 30.1% from the April 30th total of 3,320,000 shares. Based on an average daily volume of 355,000 shares, the days-to-cover ratio is currently 12.2 days. Currently, 13.6% of the company's stock are short sold. View MoonLake Immunotherapeutics' Short Interest. When is MoonLake Immunotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our MLTX earnings forecast. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) released its quarterly earnings data on Monday, March, 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.33) by $0.02. What ETFs hold MoonLake Immunotherapeutics' stock? ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include BlackRock Future Health ETF (BMED) and First Trust IPOX Europe Equity Opportunities ETF (FPXE). What is MoonLake Immunotherapeutics' stock symbol? MoonLake Immunotherapeutics trades on the NASDAQ under the ticker symbol "MLTX." Who are MoonLake Immunotherapeutics' major shareholders? MoonLake Immunotherapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (1.58%), Federated Hermes Inc. (1.53%), FMR LLC (0.90%), JPMorgan Chase & Co. (0.58%), AXA S.A. (0.57%) and Great Point Partners LLC (0.53%). View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MoonLake Immunotherapeutics' stock price today? One share of MLTX stock can currently be purchased for approximately $29.18. How much money does MoonLake Immunotherapeutics make? MoonLake Immunotherapeutics (NASDAQ:MLTX) has a market capitalization of $1.54 billion. The company earns $-49,970,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. How can I contact MoonLake Immunotherapeutics? The official website for the company is www.moonlaketx.com. The company can be reached via phone at 41-41-510-8022 or via email at ir@moonlaketx.com. This page (NASDAQ:MLTX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.